Skip to content

clinical studies to evaluate the efficacy and safety of MegaShield using for anti-adhesion after total thyroidectomy

Double-blind,Multi-center randomization, prospective confirmatory clinical studies to evaluate the efficacy and safety of MegaShield using for anti-adhesion after total thyroidectomy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0003204
Enrollment
140
Registered
2018-09-21
Start date
2018-10-05
Completion date
Unknown
Last updated
2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Eligible patient according to inclusion/exclusion criteria is enrolled and assigned by randomization code. (3 digit), On operaiton day, investigator oeprates total thyroidectomy and t

Sponsors

L&C BIO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) patient who gives written informed consent spontaneously (2) between 20 and 70 years of age (3) patient who can participate the clinical trial (4) patient diagnosed with thyroid disease who will undergo total thyroidectomy (5) Naive patients to thyroid surgery (6) During screening test, normal in liver and kidney condition (7) Childbearing potential female patients who give the consent for contraception during the study

Exclusion criteria

Exclusion criteria: (1)Pregnant or breast-feeding female patients (2) Severe liver or kidney disease (3) Lymphatid fluid or blood coagulation disease patient or coagulation medication patient (4) current medication of Anti-diabetics (5) Auto immune disease of immune suppressed patient (6) severe health conditions (7) Accompanied operation expected patient (8) current anti-cancer treatment (9) other anti-adhesion treatment (10) inappropriate patient by investigator's decision

Design outcomes

Primary

MeasureTime frame
Swallowing function test is evaluated using Marshmallow esophagography.

Secondary

MeasureTime frame
clinical symptoms evaluation through questionaire;Safety evaluation : all of adverse events collected and evaluated

Countries

Korea, Republic of

Contacts

Public ContactKeeHyun Nam

Yonsei University Health System, Severance Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 11, 2026